9 July 2015.
The Generic Medicines Industry Association (GMiA) today welcomes its newest member, Amneal Pharmaceuticals. The addition of Amneal recognises the prominent role of the GMiA and its strength in representing its members with government.
The GMiA’s strong leadership and the certainty provided to the generic medicines sector by the Strategic Agreement provides a clear roadmap for engagement between GMiA members and government over the next 5 years.
“Our Strategic Agreement with the Australian Government cements GMiA as a key stakeholder within the pharmaceutical sector, providing a singular united voice of representation for our members on issues regarding generic medicines and biosimilars,” said GMiA Chairman, Mark Crotty.
“GMiA welcomes Amneal and we look forward to welcoming even more members in the coming months.”
Amneal Managing Director Gavin Upiter said: “Following Amneal’s launch in August 2014, we have introduced a progressive offering to our customers that is compelling, different and above all offers true value and growth opportunities long term. Joining GMiA is part of Amneal’s plan for growth and complements our business philosophy.”
Members of GMiA ensure that all Australians are offered the highest quality generic and biosimilar medicines that provide affordable health outcomes for the benefit of all Australians. Members of GMiA are committed to making medicines affordable today, and for the future.
ENDS
